Physician profile
Sho Park
NPI 1225577661
$5,579.66
in general payments reported to CMS, 2019-2025
22 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,285 · 2023: $660 · 2024: $1,842 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,286 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,285.56 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,013.88 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $911.17 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $651.92 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $458.63 | 2024-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.23 | 2022-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $416.26 | 2022-2025 | |
| Glaxosmithkline, LLC. | $395.77 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $365.69 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $190.94 | 2022-2023 | Seglentis, Livalo |
| Gilead Sciences, INC. | $152.40 | 2023-2025 | Epclusa |
| Pfizer INC. | $134.52 | 2023-2025 | |
| Dexcom, INC. | $97.37 | 2024-2025 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $88.63 | 2025 | Fanapt, Ponvory |
| Xeris Pharmaceuticals, INC. | $58.80 | 2023-2024 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $43.01 | 2025 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $33.88 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $27.18 | 2022-2023 | |
| Corcept Therapeutics | $21.90 | 2024 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $19.69 | 2022 | |
| Amarin Pharma, INC. | $19.19 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.31 | 2023 | |
| Esperion Therapeutics, INC. | $14.29 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sho Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.